Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Files An 8-K Financial Statements and Exhibits

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Files An 8-K Financial Statements and Exhibits
Item 9.01.

Financial Statements and Exhibits.
Story continues below

(d) Exhibits.

Exhibit Number

Description

99.1 Press Release issued February 19, 2019

EXHIBIT INDEX

Exhibit Number

Description

99.1 Press Release issued February 19, 2019

INTERCEPT PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 tv514418_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Intercept Announces Positive Topline Results from Pivotal Phase 3 REGENERATE Study of Obeticholic Acid in Patients with Liver Fibrosis Due to NASH   First and largest successful pivotal Phase 3 study in patients with liver fibrosis due to NASH   OCA achieves primary endpoint demonstrating statistically significant improvement in liver fibrosis without worsening of NASH at 18 months (p=0.0002)   Intercept intends to file for regulatory approval in the U.S. and Europe in the second half of 2019   Results to be presented at European Association for the Study of the Liver 2019 International Liver Congress   Intercept to host conference call at 8:00 a.m. ET   NEW YORK,…
To view the full exhibit click here

About Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

An ad to help with our costs